Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Reconstitution practice and delivered dose — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-114/3
Series
Public comment period
Version
1.0
Published
27 Mar 2026
Last reviewed
27 Mar 2026
Next review
27 Mar 2027
Identifier
10.71829/cei.cp.114
Certainty
Not rated
Cycle
2026 Q1
Window
08 Jan 2026 – 09 Mar 2026
Status
Closed
Submissions
9

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-RECONSTITUTI/009Dr Gaspard WintringhamDeclared interests should appear on the document rather than on a separate pageNoted, no amendment
DRAFT-RECONSTITUTI/003Dr Sigrún LavrentievThe document is unreadable without specialist trainingAccepted in part
DRAFT-RECONSTITUTI/005Dr Yehudit YorkstoneThe same concern is used to downgrade in two domainsAccepted in part
DRAFT-RECONSTITUTI/006Dr Melisande Thorsby-NakamuraStudies not published in English were excluded without assessmentAccepted in part
DRAFT-RECONSTITUTI/007Dr Jacinta Grünbaum-SowandeAn indirect comparison is presented without an assessment of transitivityAccepted
DRAFT-RECONSTITUTI/008Dr Lorcan Uttridge industryThe document should not describe uses outside the approved indicationNot accepted
DRAFT-RECONSTITUTI/004Radoslava Palmgren-Kofi industryA sponsor trial meeting the eligibility criteria was excludedAccepted in part
DRAFT-RECONSTITUTI/001Dr Jacinta Steenkamp-FerreiraPatient-reported outcomes are collected by the trials and not reported by the reviewAccepted in part
DRAFT-RECONSTITUTI/002Dr Mordecai Bellingham-OjoOverlapping primary studies across included reviews are counted more than onceAccepted
9 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted2The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part5Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. The document is unreadable without specialist training — arising from DRAFT-RECONSTITUTI/003. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
  2. The same concern is used to downgrade in two domains — arising from DRAFT-RECONSTITUTI/005. The rating for the first outcome has been raised by one level and the domain reasoning restated, and the reasoning for the second has been rewritten to make clear that the two downgrades rest on different features of the evidence.
  3. Studies not published in English were excluded without assessment — arising from DRAFT-RECONSTITUTI/006. Language restriction is removed from the protocol for the series, the records previously excluded on that ground are listed with their screening outcome, and the residual limitation is stated in the abstract of this review.
  4. An indirect comparison is presented without an assessment of transitivity — arising from DRAFT-RECONSTITUTI/007. Transitivity is now assessed against a stated list of effect modifiers and reported before any indirect estimate, and where the assessment fails the contrast is reported as unestimable with the reason rather than estimated with a caveat.
  5. A sponsor trial meeting the eligibility criteria was excluded — arising from DRAFT-RECONSTITUTI/004. The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified…
  6. Patient-reported outcomes are collected by the trials and not reported by the review — arising from DRAFT-RECONSTITUTI/001. Patient-reported outcomes measured by any contributing trial are now reported narratively by instrument, with the instrument named and its minimum important difference stated where one is published, and the absence of a pooled estimate explained.
  7. Overlapping primary studies across included reviews are counted more than once — arising from DRAFT-RECONSTITUTI/002. Overlap between included reviews is now assessed at primary-study level and reported in a citation matrix, and participant totals are reported for the union of primary studies rather than as a sum across reviews.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.